Abstract: Human purinergic Gprotein-coupled receptor P2Y 1 (P2Y 1 R) is activated by adenosine 5'-diphosphate (ADP) to induce platelet activation and therebys erves as an important antithrombotic drug target. Crystal structures of P2Y 1 R revealed that one ligand (MRS2500) binds to the extracellular vestibule of this GPCR, whereas another (BPTU) occupies the surface between transmembrane (TM) helices TM2 and TM3. We introduced at otal of 20 msa ll-atom long-timescale molecular dynamic (MD) simulations to inquire why two molecules in completely different locations both serve as antagonists while ADP activates the receptor.O ur results indicate that BPTU acts as an antagonist by stabilizing extracellular helix bundles leading to an increase of the lipid order,w hereas MRS2500 blocks signaling by occupying the ligand binding site.B oth antagonists stabilizea ni onic lock within the receptor.However,binding of ADP breaks this ionic lock,forming acontinuous water channel that leads to P2Y 1 R activation.
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G-protein-coupled receptors (GPCRs) participate in awide spectrum of physiological functions by transmitting signals from an extracellular binding site to the cytoplasm. Thus, GPCRs are among the most important targets for modern therapeutics,c onstituting at least one third of all marketable drugs. [1] While there is considerable interest in understanding how drugs that bind to different regions of the same GPCR can produce identical responses,t he molecular basis of this phenomenon remains obscure.H erein, we used P2Y 1 R, af amily AG PCR, to investigate this question. Human purinergic GPCRs are divided into two subfamilies,P 2Y 1 Rlike receptors coupled to G q proteins,a nd P2Y 12 R-like receptors coupled to G i proteins. [2] Both are activated by ADP to trigger glutamate release,which plays acrucial role in thrombus formation. [2] Moreover,blockade of either receptor significantly decreases ADP-induced platelet aggregation. However,inhibitors of P2Y 1 Rs offer asafety advantage over P2Y 12 Rinhibitors by reducing the liability of bleeding. [2, 3] TheP2Y 1 Rcomplex crystal structures show that there are two allosteric antagonists that bind at two different regions of the receptor:1 )MRS2500 (Scheme 1; Supporting Information, Figure S1 ), completely blocks ADP-induced platelet aggregation, effectively decreases arterial thrombosis, [4] and binds on the surface of the ECL2 loop.2)BPTU substantially reduces platelet aggregation [5] and binds between two helix bundles.
To address structural and mechanistic questions about P2Y 1 R, we performed at otal of 20 msa tomic-level MD simulations (Table S1 ) on the human P2Y 1 receptor,s tarting from its crystal structures (PDB:4 XNW,4 XNV): [2] P2Y 1 R 1) bound to BPTU (P2Y 1 R*-BPTU);2 )bound to MRS2500 (P2Y 1 R-MRS2500);a nd 3) bound to agonist (P2Y 1 R-ADP, P2Y 1 R*-ADP;F igure 1). From these simulations,w ec on- clude that the two different allosteric antagonists exert their effects by either stabilizing part of the extracellular helix bundles,which lead to an increase in the lipid order (BPTU), or occupying the ligand-binding site (MRS2500). Both antagonists stabilize an ionic lock within the receptor.I n contrast, the agonist molecule ADP induces breakage of the ionic lock and then formation of acontinuous water channel that results in the activation of P2Y 1 R.
[6]
To sample the binding mode of the agonist molecule,w e placed an ADP at the P2Y 1 Rextracellular vestibule entrance, approximately 15 f rom the orthosteric site.T hen we performed 62msa ll-atom long-timescale MD simulations for this system ( Figure 1A ,B,E). Thefinal poses of the ligands converged well in each simulation ( Figure S2 ). Thea romatic purine ring of ADP engaged in p-p stacking with Y303 7.32 , whereas its ribose sugar ring formed an H-bond network with Y303 7.32 through the bulk water molecules.Strong interactions occurred between the negatively charged pyrophosphate and several positively charged residues,i ncluding K41 .T his observed binding mode is consistent with extensive mutagenesis data indicating that mutations of these residues decrease the binding affinity of ADP. [2, 7] We then executed 22mss imulations for two additional antagonist-bound systems,n amely P2Y 1 R-MRS2500 and P2Y 1 R*-BPTU.I na ntagonist-bound P2Y 1 R-MRS2500 ( Figure 1C,F) , the MRS2500 ligand located in aspace similar to that of P2Y 1 R-ADP.The substituted purine ring of MRS2500 engaged in s-p stacking with Y303 7.32 . Additionally,t he 3'-phosphate formed an ionic lock with K46
1.46 and R195 ECL2 ,w hereas the 5'-phosphate formed an ionic lock with R287
6.38 and R310 7.39 .Inthe other antagonistbound system, P2Y 1 R*-BPTU ( Figure 1D ,G), the ligand was located at the transmembrane (TM) helix surface far away from the classic ADP-ligand-binding site.T he antagonist molecule BPTU was mainly stabilized by hydrophobic interactions with several residues,i ncluding F62 .P reviously, mutagenesis studies of these helix bundles revealed areduced P2Y 1 R-binding affinity for both antagonist ligands. [2, 8] Interestingly,w eo bserved that an ionic lock between D204 ECL2 and R310 7.39 in agonist-bound P2Y 1 R, was broken during the MD simulations ( Figure 1B and Figure S3 B,D). Both residues were confirmed by mutagenesis studies [5] [6] [7] as playing essential roles in P2Y 1 Ra ctivation. To validate whether this observation is au nique feature of agonistbound P2Y 1 R, we analyzed two antagonist-bound systems, namely P2Y 1 R-MRS2500 and P2Y 1 R*-BPTU (Figure S3 A,C) . We found that this ionic lock was stabilized throughout the entire MD simulation in both P2Y 1 R-MRS2500 and P2Y 1 R*-BPTU,i mplying that the ionic lock is crucial for P2Y 1 Ra ctivation.
We noted that the size of the binding pocket in the agonist-bound system differed from those in the antagonistbound states.T oi nvestigate the consequences of ligand binding,w ee xtracted frames of the final 0.5 msf rom each simulated system and analyzed its solvent accessible surface area (SASA;F igure 2). We found that the binding pocket of agonist-bound systems ( Figure 2B ,D) were distinctly larger than those of the antagonist-bound states (Figure 2A,C) . Specifically,the SASA in P2Y 1 R*-BPTU was about 3300 2 , slightly smaller than that of P2Y 1 R-MRS2500 with avalue of 3500 2 ( Figure 2E ). However,w hen P2Y 1 Rb ound the agonist molecule ADP,t he SASA increased to 4050 and 3800 2 in agonist-bound P2Y 1 R*-ADP and P2Y 1 R-ADP respectively,o wing to the broken D204 ECL2 -R310 7.39 ionic lock.
Because the antagonist molecule BPTU is exposed to the lipid environment between TM2 and TM3, we investigated whether the binding of ligands affects the lipid order (Figure 2F) . Interestingly,the lipid order was as low as 0.15 when the antagonist MRS2500 bound to the classic extracellular vestibule of P2Y 1 R. However,w hen the antagonist BPTU bound to the lipid vicinity around the TM2-TM3 bundles,the lipid order increased to 0.20. Moreover,i nt he two agonistbound systems P2Y 1 R*-ADP and P2Y 1 R-ADP,t he lipid orders were identical, with avalue of about 0.15. In addition, we found that the b-factor in the extracellular region of P2Y 1 R*-BPTU was noticeably smaller than in both MRS2500-and ADP-bound P2Y 1 R, which correlates with our lipid order observations ( Figure S4 ). From these combined findings,w er eached the following conclusions:W hen the allosteric antagonist BPTU attaches to the helix bundles, it stabilizes the receptor,w hich leads to the increased lipid order.I nc ontrast, when MRS2500 binds to the classic extracellular vestibule,t he lipid order remains relatively low and the antagonist executes its function by occupying the binding pocket. Finally,when the ADP agonist binds to the receptor, the lipid order becomes altered owing to TM movements after activation.
Water molecules have been shown to play important roles during the GPCR activation process. [6f, 9] In this work, we also observed distinct water channels inside the receptor ( Figure S5 ). In antagonist-bound P2Y 1 R*-BPTU ( Figure S5 A,E), the extracellular ligand-binding pocket was filled with water molecules. However,i nt he intracellular zone next to the highly conserved Y324 7.53 ,ah ydrophobic layer with at hickness of 8 was observed. About 12 water molecules were found within 5of Y324 7 .53 in P2Y 1 R*-BPTU.I n contrast, when the agonist ADP bound to the same structure (P2Y 1 R*-ADP), it induced ac ontinuous water channel in this region (Figure S5 B,F) and the number of water molecules increased to 24 in the corresponding space.I na ntagonistbound P2Y 1 R-MRS2500, the number of water molecules stabilized at about 12 and ahydrophobic layer around 10 w as observed. However,i nt he corresponding agonist system P2Y 1 R-ADP,t he number of water molecules increased to 21 and acontinuous water channel also formed at the end of the MD simulations. Furthermore,w en oted that ah ighly conserved Tyr residue,Y324
7.53 at the NPxxY motif,underwent aconformational switch in agonist-bound P2Y 1 R( Figure S6 ). This occurred at 0.8-1.2 msM Dt ime scale.H owever,i nb oth bound antagonists P2Y 1 R*-BPTU and P2Y 1 R-MRS2500, the conformation of Y324 7.53 did not change during the entire simulations.T hese results agree with previous findings [9] showing that Y324 7.53 plays ar ole as as witch, forming acontinuous water channel during GPCR activation.
We also noted that the b-factor of intracellular helix bundles (Figure S4 B,D) of agonist-bound systems was much higher than that of antagonist-bound systems (Figure S4 A,C) , implying that the intracellular helices undergo considerable movement in the activated state.Inagonist-bound P2Y 1 R, we found that several trans-membrane helixes underwent striking shifts including:T M3, % 2;T M5, % 4;T M6, % 7; and TM7 % 5 ( Figure 3 ). Because TM3, TM6, and TM7 directly contact the G a protein and exert an essential role in GPCR activation, [10] we plotted the distances between different pairs of helices ( Figure 3B ). This strategy identified three distinct states of P2Y 1 Ra ctivation:t he inactive,t he intermediate,a nd the active states ( Figure 3B ). In the inactive state,t he average distances between each TM region were low: d (TM3-TM6 Interestingly,the helix movements led to obvious changes in the residue interaction network ( Figure S7) . Analyses of the interactions between residue side chains revealed that in both antagonist-bound complexes P2Y 1 R*-BPTU and P2Y 1 R-MRS2500, most of the residues inside the receptor were in contact with multiple neighbors (Figure S7 A,C) . In contrast, in the agonist-bound complexes P2Y 1 R-ADP and P2Y 1 R*-ADP, (Figure S7 B,D) , interactions between the side chains inside the receptor were disrupted by helix shifting (Figure 3 ) and the accompanying water influx ( Figure S5 ), dispersing the side chain interactions into smaller local groups indicative of larger inner void spaces.R esidues without any contacts were found preferentially on surfaces or in loops of the receptor.
To aid in further interpretation and quantification of statespecific couplings,w ec onstructed correlation networks in which each node represents acluster of protein residues,and each connecting edge is weighted by the correlation value between the two clusters ( Figure 4 ). This approach has been used successfully to unravel allosteric couplings in arange of systems. [11] In both antagonist-bound P2Y 1 Rs ( Figure 4A ,C), there were more nodes than in the agonist-bound systems:13 nodes were found in P2Y 1 R*-BPTU,and the same number in P2Y 1 R-MRS2500.
However,i nb oth agonist systems P2Y 1 R*-ADP and P2Y 1 R-ADP,o nly 8n odes were observed. Moreover,t here were fewer large nodes in antagonist systems than in agonist systems because several smaller nodes had merged after agonist binding.S pecifically,t he separate nodes in intracellular TM6-TM7 were grouped into as ingle node in the agonist-bound systems.S imilar phenomena also occurred at both the extracellular section of TM6-TM7 and the intracellular section of TM2-TM4. These observations are consistent with the MD simulation results showing that intracellular TM6 and TM7 undergo the same collective motions.
In summary,onthe basis of atotal of 20 msall-atom longtimescale MD simulations ( Figure 5 ), we found that both antagonist molecules can stabilize an ionic lock between K46
1.46 and R195 ECL2 inside the receptor via different mechanisms:B PTU acts as an antagonist by stabilizing the extracellular helix bundles to increase the lipid order,whereas MRS2500 blocks signaling by occupying the ligand-binding site.T he SASA of both antagonist-bound systems were smaller than the comparable agonist-bound systems.W hen the ADP agonist bound to the P2Y 1 R, it induced breakage of the ionic lock and increased the SASA, inducing abulk water influx into the binding pocket. Consequently,t he rotamer of highly conserved Y324 7.53 underwent am olecular switch and ac ontinuous water channel formed inside the receptor. Finally,TM3, TM6, and TM7 shifts in the cytoplasmic region created al arge void for Gp rotein binding with subsequent activation of the receptor.These findings provide new insights into the molecular changes and actions of GPCR allosteric ligands.S uch insights are applicable to innovative drug discovery.
Experimental Section
MD simulations.A ll membrane systems were built with the membrane building tool in Schrodinger Maestro [12] software with each receptor structurep re-aligned in the OPM (Orientationso fProteins in Membranes) database. [13] Pre-equilibrated 128 POPC lipids coupled with 9,800 TIP3P water molecules in ap eriodic box of 70 70 96 were used to build the protein/membrane system. Proteins,l ipids,w ater moleculesa nd ions were modelled with the CHARMM36 force field [14] parameters et, and the ligands were modelled with the CHARMM CGenFF small molecule force field. [15] All of the ligands were submitted to the GAUSSIAN 09 program [16] for structureo ptimization at the B3LYP/6-31G* level prior to force field parameter generation. All of the bond lengths to hydrogen atoms in each protein/membrane system were constrained with M-SHAKE. [17] Va nder Waals and short-rangee lectrostatici nteractions were cut off at 10 . Results obtained from the MD simulations were analyzed in Gromacs [18] and VMD. [19] Figure 5. Molecular mechanism of action inferred from the P2Y 1 R structure. The big dots represent water molecules close to the front on the Figure, whereas 
